Most Read Articles
Audrey Abella, one month ago
Fixed-dose combinations of long-acting β2-agonist (LABA) and muscarinic antagonist (LAMA) offered superior efficacy and comparable safety to LAMA or LABA/inhaled corticosteroid (ICS), the two most commonly prescribed first-line treatments for stable moderate-to-very-severe chronic obstructive pulmonary disease (COPD), according to a meta-analysis.
one year ago
At a recent continuing medical education programme, Dr Neil G Snowise, Regional Medical Leader of GlaxoSmithKline Global Respiratory Franchise shed light on the clinical efficacy of Relvar® Ellipta® (fluticasone furoate/vilanterol) for the management of asthma. Highlights of his presentation are summarized below.
one year ago
Afatinib is a potential treatment for metastatic squamous cell carcinoma, a review states.
Christina Lau, one year ago

Weight loss through a customized lifestyle modification programme provides sustained reductions in the severity of obstructive sleep apnoea (OSA) in obese patients.

CRP, ferritin levels may distinguish patients with positive sputum cultures 60 days after ATT

3 months ago
Reduce TB prevalence to 10 per 100,000 by 2022

Circulating levels of C-reactive protein (CRP) and ferritin are elevated in patients with tuberculosis (TB) starting antituberculosis therapy (ATT) and decrease over time, a new study shows. However, those that still had positive cultures after 60 days of ATT show elevated levels of these markers.

The longitudinal cohort study involved 165 pulmonary (75.7 percent male; median age 40 years) TB patients initiating ATT and between the ages of 18 and 60. Those who were taking antituberculosis medication, had type 1 diabetes mellitus, renal failure, were receiving peritoneal or haemodialysis, and pregnant were excluded.

Cryopreserved serum samples were used to measure serum levels of CRP and ferritin. Sputum samples were also collected from participants and were assessed for the respective mycobacterial loads. The associations between these parameters and sputum conversion at 60 days after ATT were evaluated.

Among all the comorbidities, anaemia (75 percent), HIV/AIDS (10 percent), type 2 diabetes (3 percent) and chronic obstructive pulmonary disease (3 percent) were the most common. Active smoking, chronic alcoholism and illicit drug use were reported in 73, 59.4 and 28.5 percent, respectively, of the study population.

Prospective analysis showed a drop in CRP levels from day 0 to day 30 of ATT (p<0.001); this trend continued to day 60 but was not significant. Levels of ferritin at day 60 was significantly reduced compared to its levels at day 0 (p<0.001) and day 30 (p<0.05). Ferritin and CRP were significantly correlated at pretreatment (p<0.0001), day 30 (p=0.001) and day 60 (p<0.0001).

Patients with negative sputum cultures at day 60 of ATT showed a decreasing trend in the levels of ferritin and CRP (p<0.0001 for both). On the other hand, those that had positive cultures showed a slight decreasing trend in ferritin levels (p=0.0041) and no significant trend in CRP levels.

Finally, levels of CRP (p=0.0005) and ferritin (p=0.002) were significantly greater in patients with positive sputum cultures than those with negative sputum cultures at day 60.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, one month ago
Fixed-dose combinations of long-acting β2-agonist (LABA) and muscarinic antagonist (LAMA) offered superior efficacy and comparable safety to LAMA or LABA/inhaled corticosteroid (ICS), the two most commonly prescribed first-line treatments for stable moderate-to-very-severe chronic obstructive pulmonary disease (COPD), according to a meta-analysis.
one year ago
At a recent continuing medical education programme, Dr Neil G Snowise, Regional Medical Leader of GlaxoSmithKline Global Respiratory Franchise shed light on the clinical efficacy of Relvar® Ellipta® (fluticasone furoate/vilanterol) for the management of asthma. Highlights of his presentation are summarized below.
one year ago
Afatinib is a potential treatment for metastatic squamous cell carcinoma, a review states.
Christina Lau, one year ago

Weight loss through a customized lifestyle modification programme provides sustained reductions in the severity of obstructive sleep apnoea (OSA) in obese patients.